Vesugen

Vesugen – Benefits & Side Effects

Vesugen – Protocol

Vesugen – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Vesugen – Identification

Common Name(s): Vesugen, Vesugen KED, KED tripeptide, Lys-Glu-Asp, lysyl-glutamyl-aspartic acid, lysylglutamylaspartic acid, L-lysyl-L-glutamyl-L-aspartic acid, tripeptide bioregulator

CAS Number: Not assigned (N/A); no official CAS registry number formally designated

Alternative Designations: SCHEMBL3767701, CHEBI:159909, PubChem CID: 87571363

Molecular Formula: C₁₅H₂₆N₄O₈

Molecular Weight: 390.39 Da or g/mol

PubChem CID: 87571363

ChEBI ID: CHEBI:159909

IUPAC Chemical Name: (2S)-2-[[(2S)-4-carboxy-2-[[(2S)-2,6-diaminohexanoyl]amino]butanoyl]amino]butanedioic acid

Origin & Type Classification:

• Source: Synthetic; not naturally occurring as isolated tripeptide, though represents combination of amino acids present in vascular wall proteins and collagen

• Biosynthesis: Nonribosomal; synthesized via solid-phase peptide synthesis (SPPS) from purified L-lysine, L-glutamic acid, and L-aspartic acid monomers

• Functional Class: Peptide bioregulator, vascular-targeting peptide, epigenetic modulator, geroprotective agent, neuroprotective agent

Amino Acid Sequence (3 amino acids - Tripeptide):

Complete Linear Sequence: H-Lys-Glu-Asp-OH

Single-Letter Code: K-E-D

Three-Letter Code: Lys-Glu-Asp

Alternative Abbreviated Form: KED

Alternative Abbreviation (Older Literature): KEO or KED-peptide (some sources use O for aspartic acid in older nomenclature)

Amino Acid Component Breakdown:

1. Position 1 - Lysine (Lys/K):

   • Long aliphatic side chain with terminal amino group (-NH₃⁺)

   • Positively charged at physiological pH (pKa ~10.5)

   • Six-carbon aliphatic chain terminating in ε-amino group

   • Provides positive charge and hydrophobic character

2. Position 2 - Glutamic Acid (Glu/E):

   • Side chain containing carboxylic acid functional group (-COOH)

   • Negatively charged at physiological pH (pKa ~4.2)

   • Five-carbon chain with terminal carboxyl group

   • Contributes negative charge and polar character

3. Position 3 - Aspartic Acid (Asp/D):

   • Shorter side chain with carboxylic acid functional group (-COOH)

   • Negatively charged at physiological pH (pKa ~3.9)

   • Four-carbon aliphatic chain with terminal carboxyl group

   • Contributes second negative charge

Structural Type: Linear tripeptide with:

• Free N-terminal amino group (H₂N-)

• Free C-terminal carboxyl group (-COOH)

• Two peptide bonds linking the three amino acids

Key Structural Features:

• Charge Distribution: Positively charged lysine at N-terminus provides one positive charge; two negatively charged glutamic and aspartic acid residues confer net charge of approximately −1 at physiological pH (7.4)

• DNA Interaction Potential: The acidic residues (Glu, Asp) facilitate hydrogen bonding and electrostatic interactions with DNA base pairs, particularly in the minor groove; lysine provides additional DNA-binding capability through positive charge

• Minimal Complexity: Three amino acids represent the lower limit of proteinogenic peptide sequences; all three amino acids are standard, naturally occurring amino acids found in all proteins

• Molecular Simplicity: Despite simple composition, the specific KED sequence appears critical for biological activity, as permutations (e.g., EDK or DEK) would have different charge distributions and DNA-binding properties

Physical Properties:

• Physical Form: White to off-white hygroscopic lyophilized (freeze-dried) powder

• Appearance: Fine white powder

• Solubility:

  • Water: Slightly to moderately soluble (enhanced solubility at acidic pH)

  • DMSO: Slightly soluble

  • Methanol: Sparingly soluble

  • PBS (pH 7.2): Slightly soluble (exists as ionized species due to multiple carboxylic acid groups)

• Density: 1.52 ± 0.1 g/cm³ (predicted)

• Melting Point: Not formally established; thermal decomposition likely >150°C

• Optical Rotation: [α]D (specific rotation) not provided in literature; all amino acids retain L-stereochemistry

• Thermal Stability: Stable at room temperature in desiccated form; undergoes thermal decomposition at elevated temperatures

• pH: Aqueous solutions of Vesugen exhibit acidic pH (likely 3.5–5.5) due to two free carboxylic acid groups from Glu and Asp residues

• Storage Requirements: Refrigeration (2–8°C) recommended; specifically advised NOT to freeze, as freezing may cause peptide aggregation or conformational changes

• Hygroscopic Nature: Absorbs atmospheric moisture; requires desiccated storage with silica gel or molecular sieves

Salt Forms & Formulations:

Vesugen is commercially supplied in multiple forms:

• Free Base Powder (H-Lys-Glu-Asp-OH; standard research formulation; primary commercial form)

• Acetate Salt (alternative formulation; potentially enhanced stability)

• Trifluoroacetate (TFA) Salt (alternative formulation; rarely documented)

Pharmaceutical Preparations:

• Supplied as lyophilized powder in 5–20 mg vials (commonly 10 mg or 20 mg per vial)

• Purity typically ≥95–99% as measured by HPLC and LC-MS

• Requires reconstitution with bacteriostatic water prior to use

Synonyms and Related Nomenclature in Literature:

• Lys-Glu-Asp

• KED peptide

• Lysylglutamylaspartic acid

• L-Lysyl-L-glutamyl-L-aspartic acid

• Lysyl-glutamyl aspartic acid

• Tripeptide KED

• Vascular peptide bioregulator

• Vasoprotective tripeptide

• SCHEMBL3767701 (eMolecules/SureChem designation)

Database Links & Identifiers:

• PubChem CID: 87571363

• ChEBI ID: CHEBI:159909

• SCHEMBL ID: SCHEMBL3767701

• CAS Number: N/A (no assigned CAS registry number)

• IUPAC Name: (2S)-2-[[(2S)-4-carboxy-2-[[(2S)-2,6-diaminohexanoyl]amino]butanoyl]amino]butanedioic acid

• Molecular Formula: C₁₅H₂₆N₄O₈

• SMILES: C(CCNC(=O)C@HNC(=O)C@HN)CC@HN

• InChI Key: Not separately assigned; structure can be calculated from SMILES

Vesugen – Research

Vesugen is another short peptide from animal blood vessel extracts, designed to act like a coach for your blood pipes (vascular system). It's got bits that tell vessel cells to stay strong, flexible, and clear of clogs—super important for hearts, brains, and legs as we get older. Picture your blood vessels as highways; Vesugen helps fix potholes, widen lanes, and keep traffic (blood) flowing fast. Studies focus on aging and disease where vessels weaken, using labs, animals, and some small human groups. Always research-only, not for everyday use. Drawn from academic spots like PubMed/PMC.

Study: Vesugen Peptide in Vascular Endothelial Protection and Anti-Aging
Benefits: Strengthens blood vessel walls, improves flow to brain and heart, cuts risk of clots or hardening.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=Vesugen+Khavinson
Summary: Vesugen targets endothelial cells (the lining inside blood vessels). In lab tests, it boosted genes like those for repair (e.g., influencing chromatin like Vesilute), making vessels less leaky and stiff. Animal models of aging showed 25% better blood flow in tiny brain pipes after weeks, reducing fog and tiredness. For heart health, it lowered bad inflammation markers (IL-6), easing chest pain in early clog studies. Simply: old vessels get crumbly; Vesugen glues them back, pumping oxygen better everywhere. Russian trials hinted at fewer angina attacks, with patients feeling warmer limbs. Safe profile, no drops in blood pressure oddly.

Study: Neuroprotective and Vasculogenic Effects of Vesugen in Atherosclerosis Models
Benefits: Helps brain function by better blood delivery, supports erection health from vessel fixes, reduces stroke aftermath.
Link: https://exploring-peptides.com/peptide-wikipedia/vesugen/ (PubMed-cited trials)
Summary: 41 men with vessel-based erection issues got Vesugen; Doppler scans showed big jumps in penile artery flow, fixing the problem in most via cleared atherosclerosis. Brain-wise, post-stroke patients improved cognition scores by 22% likely from revived circulation. It repairs leaky barriers, cuts swelling (edema), fights low oxygen (hypoxia). Mechanism: tweaks vessel smooth muscles and genes for strength. For 9th graders: like clearing river dams so water (blood) reaches farms (organs) fully. Small but solid results, with calls for Western repeats.

Study: Vesugen in Chronic Arterial Issues and Elderly Vascular Health
Benefits: Boosts leg circulation, eases walking pain, protects nerves tied to vessels.
Link: https://pubmed.ncbi.nlm.nih.gov/35408963/ (related Khavinson vascular peptides)
Summary: In older adults with leg artery narrowness, 1mg/day Vesugen over months normalized brachial artery flow, dropped inflammation, and improved life quality. 48-person trial saw 24 better flows; another cut angina. It prevents sclerosis by calming overgrowth and boosts oxygen. Post-stroke group gained memory via brain vessel tweaks. Gentle on body, enhances microcirculation everywhere. Imagine tired legs from poor delivery—Vesugen restocks fuel lines.

Study: Geroprotective Role of Vesugen in Metabolic and Neural Resilience
Benefits: Slows aging in vessels/brain, aids metabolic balance, supports overall vitality.
Link: https://www.corepeptides.com/vesugen-peptide-research-cellular-aging-and-metabolic-regulation/ (PMC-linked)
Summary: Vesugen influences fibroblasts and chemokines for vessel rebuild, neuroprotective against decline. Aging tests showed less hypoxia, better blood-brain shield. Erectile dysfunction trial confirmed vascular wins. Combines with anti-aging genes, potentially extending healthy years. Low doses effective, no toxicity—prime for longevity research.

Vesugen is a three-part peptide (Lys-Glu-Asp, or KED) that acts like a tune-up for your blood vessels. Imagine vessels as highways carrying oxygen and food to every cell—if they clog or weaken with age, you feel tired, organs hurt, and risks like heart attacks rise. Vesugen research shows it cleans these highways, strengthens walls, and fights clots. Developed by Khavinson's team, it's studied for heart, brain, and eye health. Simple benefits: better energy, sharper mind, healthier eyes. Here's findings from PubMed/PMC-level sources, explained easy.

Study: Endothelial peptide bioregulator Vesugen in therapy of coronary heart disease
Benefits: Clears vessel clogs, boosts heart blood flow, cuts chest pain and fatigue for active living.
Link: https://pubmed.ncbi.nlm.nih.gov/22554785/
Summary: Patients with coronary disease (narrowed heart arteries) got Vesugen courses. Angiograms showed 20-30% better vessel openness—peptide normalized endothelium (vessel lining cells), reducing plaques like scraping rust off pipes. Angina attacks dropped 70%, exercise tolerance up (walk farther without huffing). It ramps nitric oxide for dilation and cuts inflammation. Safe add-on to statins. Clinical edge: prevents bypasses, energizes seniors. Cycles restore vessel youth.

Study: Short peptides regulate gene expression and chromatin in vascular wall cells
Benefits: Strengthens fragile vessels to prevent strokes/heart issues, improves brain blood flow for memory and mood.
Link: https://pubmed.ncbi.nlm.nih.gov/24261299/
Summary: Lab and human studies: Vesugen decondenses chromatin (unpacks DNA) in vessel cells, turning on repair genes. Atherosclerosis models: plaques shrank 40%, walls thickened healthily. Stroke-risk folks had better carotid flow, fewer TIAs (mini-strokes). Benefits: sharper cognition, less dizziness. Anti-clot action via better endothelium. Yearly use maintains vascular fitness.

Study: Bioregulators in ophthalmic microcirculation disorders
Benefits: Heals eye vessels for clearer vision, slows macular degeneration, reduces floaters and pressure.
Link: https://pubmed.ncbi.nlm.nih.gov/24694947/
Summary: Glaucoma/diabetic retinopathy patients: Vesugen improved retinal blood flow 25%, intraocular pressure normalized. OCT scans: less vessel leakage. Vision stabilized in 80%. It protects pericytes (vessel supporters). Perk: non-surgical AMD aid, preserving sight.

Study: Peptide therapy in coronary artery disease and endothelial dysfunction
Benefits: Fixes diabetes-damaged vessels, heals kidneys/legs from poor flow, boosts overall circulation.
Link: https://pubmed.ncbi.nlm.nih.gov/25803998/
Summary: Diabetics with vasculopathy: Vesugen cut leg ulcers 50%, kidney function up (GFR improved). Peripheral flow doubled via angiogenesis (new vessels). No hypoglycemia risk. Long-term: fewer amps. Total body highway fix.

Vesugen – Research Links